

# Garth Nicholas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8972946/publications.pdf>

Version: 2024-02-01

29  
papers

3,274  
citations

471509

17  
h-index

501196

28  
g-index

30  
all docs

30  
docs citations

30  
times ranked

5190  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306.	7.4	1,619
2	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	10.7	776
3	Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection) Tj ETQq1 1 0.784314 rgBT /Overl 1523-1531.	10.7	158
4	Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. <i>PLoS Medicine</i> , 2017, 14, e1002225.	8.4	114
5	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1210-1222.	1.1	112
6	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). <i>Neuro-Oncology</i> , 2020, 22, 705-717.	1.2	47
7	Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study. <i>Chest</i> , 2016, 150, 1015-1022.	0.8	45
8	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	1.6	40
9	Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not. <i>Lung Cancer</i> , 2016, 97, 15-21.	2.0	39
10	Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. <i>Lung Cancer</i> , 2018, 120, 142-148.	2.0	37
11	A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non-Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. <i>Clinical Lung Cancer</i> , 2014, 15, 52-57.	2.6	32
12	Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. <i>BMJ Open</i> , 2019, 9, e024719.	1.9	32
13	Plasma pro-surfactant protein B and lung function decline in smokers. <i>European Respiratory Journal</i> , 2015, 45, 1037-1045.	6.7	30
14	Radiological and Pathological Features Associated with IDH1-R132H Mutation Status and Early Mortality in Newly Diagnosed Anaplastic Astrocytic Tumours. <i>PLoS ONE</i> , 2015, 10, e0123890.	2.5	24
15	Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. <i>Journal of Clinical Oncology</i> , 2019, 37, 461-470.	1.6	23
16	The Impact of Baseline Edmonton Symptom Assessment Scale Scores on Treatment and Survival in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e91-e99.	2.6	22
17	Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. <i>Lung Cancer</i> , 2019, 133, 48-55.	2.0	19
18	Inhibition of glioblastoma malignancy by Lgl1. <i>Oncotarget</i> , 2014, 5, 11541-11551.	1.8	16

#	ARTICLE	IF	CITATIONS
19	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	1.6	15
20	Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. <i>Frontiers in Oncology</i> , 2021, 11, 671972.	2.8	14
21	Systemic Therapy Outcomes in Adult Patients with Ewing Sarcoma Family of Tumors. <i>Case Reports in Oncology</i> , 2017, 10, 462-472.	0.7	13
22	Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population. <i>BMC Pulmonary Medicine</i> , 2020, 20, 300.	2.0	12
23	The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103540.	4.4	11
24	Avelumab in newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab118.	0.7	8
25	Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100130.	1.7	6
26	A prospective intervention to improve happiness and reduce burnout in oncologists. <i>Supportive Care in Cancer</i> , 2019, 27, 1563-1572.	2.2	6
27	Avelumab in newly diagnosed glioblastoma multiforme: The SEJ study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13571-e13571.	1.6	3
28	The influence of season and distance to a cancer centre on lung cancer treatment rates. <i>Cancer Treatment and Research Communications</i> , 2017, 12, 25-31.	1.7	1
29	ATIM-12. AVELUMAB IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME-THE SEJ STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi4-vi4.	1.2	0